RecruitingNCT06517719

Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

Real-world Experience With Lutetium (177Lu) Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer, an Observational, Multicenter, Prospective Cohort Study

Sponsor

Novartis Pharmaceuticals

Enrollment

500 participants

Start Date

Sep 4, 2024

Study Type

OBSERVATIONAL

Conditions

Metastatic Castration-resistant Prostate Cancer

Summary

The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This real-world study is collecting information on how lutetium-177 PSMA therapy (a targeted radioactive treatment) performs in everyday clinical practice for men with metastatic castration-resistant prostate cancer (mCRPC) — meaning prostate cancer that has spread and no longer responds to hormone therapy. **You may be eligible if...** - You are an adult male (18 or older) - You have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC) - Your doctor has decided to start you on lutetium-177 PSMA therapy (brand name Pluvicto) as part of your standard care - You are willing to complete quality-of-life questionnaires for 1 year after treatment **You may NOT be eligible if...** - You are receiving lutetium-177 PSMA as part of a different clinical trial - You do not meet your country's approved label for this treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERlutetium (177Lu) vipivotide tetraxetan

This is an observational study. There is no treatment allocation. The decision to initiate lutetium vipivotide tetraxetan will be based solely on clinical judgement.

Locations(37)

Novartis Investigative Site

Konstanz, Baden-Wurttemberg, Germany

Novartis Investigative Site

Stuttgart, Baden-Wurttemberg, Germany

Novartis Investigative Site

Munich, Bavaria, Germany

Novartis Investigative Site

Regensburg, Bavaria, Germany

Novartis Investigative Site

Würzburg, Bavaria, Germany

Novartis Investigative Site

Cottbus, Brandenburg, Germany

Novartis Investigative Site

Frankfurt (Oder), Brandenburg, Germany

Novartis Investigative Site

Ludwigshafen, Germany, Germany

Novartis Investigative Site

Marburg, Hesse, Germany

Novartis Investigative Site

Cologne, North Rhine-Westphalia, Germany

Novartis Investigative Site

Dresden, Saxony, Germany

Novartis Investigative Site

Leipzig, Saxony, Germany

Novartis Investigative Site

Halle, Saxony-Anhalt, Germany

Novartis Investigative Site

Jena, Thuringia, Germany

Novartis Investigative Site

Aachen, Germany

Novartis Investigative Site

Augsburg, Germany

Novartis Investigative Site

Berlin, Germany

Novartis Investigative Site

Berlin, Germany

Novartis Investigative Site

Berlin, Germany

Novartis Investigative Site

Bielefeld, Germany

Novartis Investigative Site

Bonn, Germany

Novartis Investigative Site

Chemnitz, Germany

Novartis Investigative Site

Dortmund, Germany

Novartis Investigative Site

Dortmund, Germany

Novartis Investigative Site

Erfurt, Germany

Novartis Investigative Site

Erlangen, Germany

Novartis Investigative Site

Essen, Germany

Novartis Investigative Site

Fulda, Germany

Novartis Investigative Site

Herford, Germany

Novartis Investigative Site

Homburg, Germany

Novartis Investigative Site

Magdeburg, Germany

Novartis Investigative Site

Mainz, Germany

Novartis Investigative Site

Nuremberg, Germany

Novartis Investigative Site

Rostock, Germany

Novartis Investigative Site

Trier, Germany

Novartis Investigative Site

Tübingen, Germany

Novartis Investigative Site

Ulm, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06517719

Related Trials

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779240 locations

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

NCT07213674134 locations

Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

NCT076410491 location

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT0728715032 locations

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT072883599 locations